What type of study is this?

This is a Meta-Analysis study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

The study aims to explore the LumB-specific benefits of entinostat in HR+ breast cancer through molecular mechanisms.

March 8, 2026Open Access

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals DNMT3A mechanism in entinostat's benefit for LumB subtype in breast cancer, suggesting patient selection strategies.

The study aims to explore the LumB-specific benefits of entinostat in HR+ breast cancer through molecular mechanisms.
Examined entinostat effects in Luminal A and B PAM50 subtypes
Used Waddington landscape analysis on single cancer cells
Replicated findings in METABRIC dataset of breast cancer patients
Entinostat benefits are specific to LumB subtype with a highlighted role of DNMT3A
Significant difference in co-expression of DNMT3A in LumB compared to LumA
Support for stratified patient population predicted by NCT07235618 trial

Eric Robert Lawson (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals DNMT3A mechanism in entinostat's benefit for LumB subtype in breast cancer, suggesting patient selection strategies.